Emerging pharmacological therapies for prevention and early treatment of acute lung injury

Enrique Ortiz-Diaz, Emir Festic, Ognjen Gajic, Joseph E. Levitt

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are serious complications of acute illness and injury, associated with an inpatient mortality of up to 40%. Despite considerable basic science and clinical research, therapeutic options for established ALI are limited. Survivors of ARDS are often faced with poor health-related quality of life, depressive-anxiety disorders, cognitive deficits, and financial strain. An attractive approach toward managing ALI lies in its prevention and early treatment. In addition to improving recognition of at-risk patients, it is necessary to identify novel treatments targeting the pathways that may prevent or ameliorate lung injury. The rationale and animal and clinical evidence for aspirin, systemic and inhaled steroids, β-agonists, renin-angiotensin axis blockers, statins, peroxisome proliferator agonist receptor ligands, curcumin, and inhaled heparin are included in this narrative review. Randomized, controlled trials are currently being designed and implemented to address their efficacy in populations at risk for ALI.

Original languageEnglish (US)
Pages (from-to)448-458
Number of pages11
JournalSeminars in Respiratory and Critical Care Medicine
Volume34
Issue number4
DOIs
StatePublished - 2013

Fingerprint

Acute Lung Injury
Pharmacology
Adult Respiratory Distress Syndrome
Peroxisome Proliferators
Therapeutic Human Experimentation
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Curcumin
Angiotensins
Lung Injury
Therapeutics
Depressive Disorder
Anxiety Disorders
Renin
Aspirin
Survivors
Heparin
Inpatients
Randomized Controlled Trials
Steroids
Quality of Life

Keywords

  • acute lung injury
  • acute respiratory distress syndrome
  • lung injury prediction score
  • multiorgan dysfunction syndrome

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Emerging pharmacological therapies for prevention and early treatment of acute lung injury. / Ortiz-Diaz, Enrique; Festic, Emir; Gajic, Ognjen; Levitt, Joseph E.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 34, No. 4, 2013, p. 448-458.

Research output: Contribution to journalArticle

@article{d72f357163ae49f980976099b4aa7dd0,
title = "Emerging pharmacological therapies for prevention and early treatment of acute lung injury",
abstract = "Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are serious complications of acute illness and injury, associated with an inpatient mortality of up to 40{\%}. Despite considerable basic science and clinical research, therapeutic options for established ALI are limited. Survivors of ARDS are often faced with poor health-related quality of life, depressive-anxiety disorders, cognitive deficits, and financial strain. An attractive approach toward managing ALI lies in its prevention and early treatment. In addition to improving recognition of at-risk patients, it is necessary to identify novel treatments targeting the pathways that may prevent or ameliorate lung injury. The rationale and animal and clinical evidence for aspirin, systemic and inhaled steroids, β-agonists, renin-angiotensin axis blockers, statins, peroxisome proliferator agonist receptor ligands, curcumin, and inhaled heparin are included in this narrative review. Randomized, controlled trials are currently being designed and implemented to address their efficacy in populations at risk for ALI.",
keywords = "acute lung injury, acute respiratory distress syndrome, lung injury prediction score, multiorgan dysfunction syndrome",
author = "Enrique Ortiz-Diaz and Emir Festic and Ognjen Gajic and Levitt, {Joseph E.}",
year = "2013",
doi = "10.1055/s-0033-1351118",
language = "English (US)",
volume = "34",
pages = "448--458",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Emerging pharmacological therapies for prevention and early treatment of acute lung injury

AU - Ortiz-Diaz, Enrique

AU - Festic, Emir

AU - Gajic, Ognjen

AU - Levitt, Joseph E.

PY - 2013

Y1 - 2013

N2 - Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are serious complications of acute illness and injury, associated with an inpatient mortality of up to 40%. Despite considerable basic science and clinical research, therapeutic options for established ALI are limited. Survivors of ARDS are often faced with poor health-related quality of life, depressive-anxiety disorders, cognitive deficits, and financial strain. An attractive approach toward managing ALI lies in its prevention and early treatment. In addition to improving recognition of at-risk patients, it is necessary to identify novel treatments targeting the pathways that may prevent or ameliorate lung injury. The rationale and animal and clinical evidence for aspirin, systemic and inhaled steroids, β-agonists, renin-angiotensin axis blockers, statins, peroxisome proliferator agonist receptor ligands, curcumin, and inhaled heparin are included in this narrative review. Randomized, controlled trials are currently being designed and implemented to address their efficacy in populations at risk for ALI.

AB - Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are serious complications of acute illness and injury, associated with an inpatient mortality of up to 40%. Despite considerable basic science and clinical research, therapeutic options for established ALI are limited. Survivors of ARDS are often faced with poor health-related quality of life, depressive-anxiety disorders, cognitive deficits, and financial strain. An attractive approach toward managing ALI lies in its prevention and early treatment. In addition to improving recognition of at-risk patients, it is necessary to identify novel treatments targeting the pathways that may prevent or ameliorate lung injury. The rationale and animal and clinical evidence for aspirin, systemic and inhaled steroids, β-agonists, renin-angiotensin axis blockers, statins, peroxisome proliferator agonist receptor ligands, curcumin, and inhaled heparin are included in this narrative review. Randomized, controlled trials are currently being designed and implemented to address their efficacy in populations at risk for ALI.

KW - acute lung injury

KW - acute respiratory distress syndrome

KW - lung injury prediction score

KW - multiorgan dysfunction syndrome

UR - http://www.scopus.com/inward/record.url?scp=84881570747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881570747&partnerID=8YFLogxK

U2 - 10.1055/s-0033-1351118

DO - 10.1055/s-0033-1351118

M3 - Article

C2 - 23934714

AN - SCOPUS:84881570747

VL - 34

SP - 448

EP - 458

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 4

ER -